Engineered living cells as therapeutic agents are transforming medicine. An emerging focus is tumor-colonizing bacteria, where microbes have been demonstrated to selectively grow within solid tumors. This natural tropism presents a unique opportunity to engineer bacteria as programmable drug delivery vehicles. I will describe our recent efforts to enhance bacterial cancer therapies using synthetic biology approaches. Novel technologies utilize a multiscale framework and advance bacteria as next generation therapeutics.
Learning Objectives:
understand latest technologies in pharamaceutical sciences
